However, development of monoclonal antibodies to target extracellular IL-32 or adaption of siRNA approaches (79) to knockdown intracellular IL-32 expression would allow this question to be addressed in both T1D and other autoimmune diseases where current evidence suggests a crucial role for IL-32. Here, IL32 is linked to autoimmune disease.